Sunitinib: ten years of successful clinical use and study in advanced renal cell carcinoma
RJ Motzer, B Escudier, A Gannon, RA Figlin - The oncologist, 2017 - academic.oup.com
The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
[HTML][HTML] Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma
RJ Motzer, B Escudier, A Gannon, RA Figlin - The Oncologist, 2017 - ncbi.nlm.nih.gov
The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
RJ Motzer, B Escudier, A Gannon, RA Figlin - Oncologist, 2017 - search.ebscohost.com
The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
[PDF][PDF] Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma
RJ Motzer, B Escudier, A Gannon, RA Figlin - The Oncologist, 2017 - Wiley Online Library
The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma
RJ Motzer, B Escudier, A Gannon… - The oncologist, 2017 - pubmed.ncbi.nlm.nih.gov
The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
RJ Motzer, B Escudier, A Gannon, RA Figlin - The Oncologist, 2016 - europepmc.org
The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
RJ Motzer, B Escudier, A Gannon, RA Figlin - Oncologist, 2017 - search.ebscohost.com
The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
RJ Motzer, B Escudier, A Gannon, RA Figlin - The Oncologist, 2016 - europepmc.org
The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …
Administration in January 2006 for use in patients with advanced renal cell carcinoma …